BOSTON--(BUSINESS WIRE)--Astria Therapeutics ... today announced the initiation of the ALPHA-ORBIT Phase 3 clinical trial of navenibart in people living with hereditary angioedema (HAE).

Try refreshing your browser, or tap here to see other videos from our team. SES and Quvia are integrating SES’s Adaptive Resource Control (ARC) system with Quvia’s Grid and Network Capacity Controller ...